Pay in 4 interest-free payments of $7.44 Learn more
Ships within 48 hours · Estimated delivery Oct 10 - Oct 15
Beyond GLP-1, the market encompasses peptide cancer therapies (Oncology Peptide Therapy at 4.1% share, 11.79% CAGR), somatostatin analogues for neuroendocrine tumours, GnRH agonists/antagonists for hormone-sensitive cancers, radioligand therapy, and reproductive medicine peptides each representing strategically important niches with their own competitive dynamics
Most rodent studies use 10 micrograms per kilogram to 10 milligrams per kilogram administered subcutaneously or intraperitoneally
That doesn't automatically mean fat gain
Reported issues at therapeutic doses are mild and uncommon, and include local injection-site reactions, occasional dizziness, and transient changes in blood pressure [Sikiric et al., Inflammopharmacology, 2018]
While no clinical trials have examined BPC-157 for hip conditions directly, extensive preclinical work on tendons, ligaments, and muscles provides strong mechanistic support for its application to hip problems
